vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
First Foundation Inc. is the larger business by last-quarter revenue ($48.4M vs $34.1M, roughly 1.4× ZEVRA THERAPEUTICS, INC.). On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 183.4%). ZEVRA THERAPEUTICS, INC. produced more free cash flow last quarter ($5.5M vs $-35.2M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
FFWM vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $34.1M |
| Net Profit | $-8.0M | — |
| Gross Margin | — | — |
| Operating Margin | -97.5% | 27.3% |
| Net Margin | -97.9% | — |
| Revenue YoY | 421.7% | 183.4% |
| Net Profit YoY | 43.0% | — |
| EPS (diluted) | $-0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $34.1M | ||
| Q3 25 | $63.6M | $26.1M | ||
| Q2 25 | $51.4M | $25.9M | ||
| Q1 25 | $71.4M | $20.4M | ||
| Q4 24 | $9.3M | $12.0M | ||
| Q3 24 | $9.2M | $3.7M | ||
| Q2 24 | $57.5M | $4.4M | ||
| Q1 24 | $51.1M | $3.4M |
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $-146.3M | $-544.0K | ||
| Q2 25 | $-7.7M | $74.7M | ||
| Q1 25 | $6.9M | $-3.1M | ||
| Q4 24 | $-14.1M | — | ||
| Q3 24 | $-82.2M | $-33.2M | ||
| Q2 24 | $3.1M | $-19.9M | ||
| Q1 24 | $793.0K | $-16.6M |
| Q4 25 | -97.5% | 27.3% | ||
| Q3 25 | -92.7% | 15.9% | ||
| Q2 25 | -21.1% | -274.5% | ||
| Q1 25 | 8.8% | -26.3% | ||
| Q4 24 | -247.7% | -128.0% | ||
| Q3 24 | -1276.7% | -739.0% | ||
| Q2 24 | 4.6% | -534.8% | ||
| Q1 24 | -0.2% | -598.1% |
| Q4 25 | -97.9% | — | ||
| Q3 25 | -230.1% | -2.1% | ||
| Q2 25 | -15.0% | 288.7% | ||
| Q1 25 | 9.7% | -15.2% | ||
| Q4 24 | -152.2% | — | ||
| Q3 24 | -896.9% | -899.2% | ||
| Q2 24 | 5.4% | -447.9% | ||
| Q1 24 | 1.6% | -485.3% |
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-1.78 | $-0.01 | ||
| Q2 25 | $-0.09 | $1.21 | ||
| Q1 25 | $0.08 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-1.23 | $-0.69 | ||
| Q2 24 | $0.05 | $-0.48 | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $912.6M | $154.7M |
| Total Assets | $11.9B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $62.4M | ||
| Q3 25 | $1.7B | $54.4M | ||
| Q2 25 | $1.1B | $47.7M | ||
| Q1 25 | $1.0B | $37.3M | ||
| Q4 24 | $1.0B | $33.8M | ||
| Q3 24 | $1.1B | $54.0M | ||
| Q2 24 | $1.4B | $39.3M | ||
| Q1 24 | $1.6B | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $912.6M | $154.7M | ||
| Q3 25 | $917.9M | $133.2M | ||
| Q2 25 | $1.1B | $117.2M | ||
| Q1 25 | $1.1B | $41.0M | ||
| Q4 24 | $1.1B | $39.7M | ||
| Q3 24 | $1.1B | $69.8M | ||
| Q2 24 | $933.2M | $32.5M | ||
| Q1 24 | $928.7M | $48.8M |
| Q4 25 | $11.9B | $284.7M | ||
| Q3 25 | $11.9B | $270.1M | ||
| Q2 25 | $11.6B | $256.3M | ||
| Q1 25 | $12.6B | $172.7M | ||
| Q4 24 | $12.6B | $178.1M | ||
| Q3 24 | $13.4B | $191.6M | ||
| Q2 24 | $13.7B | $144.4M | ||
| Q1 24 | $13.6B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $5.5M |
| Free Cash FlowOCF − Capex | $-35.2M | $5.5M |
| FCF MarginFCF / Revenue | -72.8% | 16.1% |
| Capex IntensityCapex / Revenue | 6.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $5.5M | ||
| Q3 25 | $9.2M | $4.7M | ||
| Q2 25 | $-16.3M | $-3.6M | ||
| Q1 25 | $-552.0K | $-8.2M | ||
| Q4 24 | $-8.7M | $-16.3M | ||
| Q3 24 | $14.2M | $-18.1M | ||
| Q2 24 | $-9.1M | $-19.1M | ||
| Q1 24 | $7.2M | $-16.2M |
| Q4 25 | $-35.2M | $5.5M | ||
| Q3 25 | $8.6M | $4.2M | ||
| Q2 25 | $-16.7M | $-3.8M | ||
| Q1 25 | $-2.5M | $-8.3M | ||
| Q4 24 | $-11.4M | — | ||
| Q3 24 | $13.4M | — | ||
| Q2 24 | $-9.4M | — | ||
| Q1 24 | $5.9M | — |
| Q4 25 | -72.8% | 16.1% | ||
| Q3 25 | 13.5% | 15.9% | ||
| Q2 25 | -32.4% | -14.7% | ||
| Q1 25 | -3.5% | -40.8% | ||
| Q4 24 | -123.5% | — | ||
| Q3 24 | 146.2% | — | ||
| Q2 24 | -16.3% | — | ||
| Q1 24 | 11.6% | — |
| Q4 25 | 6.9% | 0.1% | ||
| Q3 25 | 1.0% | 2.1% | ||
| Q2 25 | 0.8% | 0.8% | ||
| Q1 25 | 2.8% | 0.5% | ||
| Q4 24 | 29.4% | 0.0% | ||
| Q3 24 | 9.0% | 0.0% | ||
| Q2 24 | 0.4% | 0.0% | ||
| Q1 24 | 2.5% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.05× | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFWM
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
